According to @stocktalkweekly, JPMorgan initiated coverage on CRISPR Therapeutics (CRSP) at Overweight with a Dec-2026 price target of $70 (source: @stocktalkweekly). The source reports JPMorgan sees CRSP nearing several portfolio inflection points, with partnered Casgevy and approximately $2 billion in cash providing valuation support (source: @stocktalkweekly). The source notes JPMorgan views CRSP’s setup and outlook as differentiated versus other gene-editing peers, with Casgevy’s commercial levers well understood (source: @stocktalkweekly). The source adds JPMorgan expects Casgevy sales to ramp and net profits to accrue to CRSP near term, and that a milder preconditioning regimen could help CRSP gain additional credit for its stake in the franchise (source: @stocktalkweekly). The source makes no mention of any cryptocurrency market impact (source: @stocktalkweekly).

According to Stock Talk (@stocktalkweekly), Citizens JMP has reiterated its 'Outperform' rating on CRISPR Therapeutics (CRSP) and set an $86 price target, following a significant gene-editing M&A deal that marks a major milestone for the technology. The report highlights recent collaborations between Eli Lilly (LLY) and Verve Therapeutics (VERV), noting growing institutional confidence in gene-editing's commercial potential. For crypto traders, the surge in biotech M&A and institutional adoption of advanced gene-editing technologies could boost market sentiment for blockchain projects focusing on healthcare or biotech tokenization, creating new cross-sector momentum. (Source: Stock Talk on Twitter, June 18, 2025)